pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,798 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT824Endpoints628BioPharma Dive239onclive165Fierce Biotech91BioSpace90raps32globenewswire health28
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • #ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project
    In 2022, Frank Fan moved more than 800 miles from Nanjing to Shenzhen, China, seeking a fresh start. He had abruptly left Legend Biotech, the CAR-T company he co-founded, just one month after the m…
    Endpoints · 2mo ago↗ source
  • Niowave’s $75M radioisotope facility; CordenPharma to buy AmbioPharm
    Plus, news about Agilent’s earnings report: ☢️ Niowave’s radioisotope factory: The company has broken ground on a $75 million production facility in Lansing, MI, which will be used to manufacture a…
    Endpoints · 2mo ago↗ source
  • Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy
    Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its CEO Birgit Girshick, other companies…
← prev
page 46 of 72
next →
fda medwatch21
fda press21
fda recalls16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 2mo ago↗ source
  • China gene editing startup YolTech raises $70M to move CRISPR therapies forward
    One of China’s most prolific gene editing companies has raised its biggest round of funding yet, ahead of plans to go public in Hong Kong. While most gene editing companies in the US trimmed their ...
    Endpoints · 2mo ago↗ source
  • Oura pushes deeper into healthcare services as part of new ring launch
    Alongside the debut of Oura's smaller Ring 5, the wearables company on Thursday unveiled its plans to help users integrate health records and translate their ring’s findings into medical care. Oura…
    Endpoints · 2mo ago↗ source
  • AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
    AbbVie said the FDA has approved an antibody-drug conjugate it obtained as part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer. On Wednesday, the ...
    Endpoints · 2mo ago↗ source
  • GSK spells out positive Phase 3 data for hepatitis B drug it licensed from Ionis
    GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews underway in four mark…
    Endpoints · 2mo ago↗ source
  • AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
    Plus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a few…
    Endpoints · 2mo ago↗ source
  • STAT+: 23andMe offers to connect users’ DNA data with medical records
    23andMe is partnering with HealthEx to allow users to import their medical records, the company said Tuesday at STAT Breakthrough Summit West.
    STAT · 2mo ago↗ source
  • STAT+: Marc Tessier-Lavigne addresses new book’s allegations about his conduct in Stanford misconduct case
    Former Stanford President Marc Tessier-Lavigne responded publicly for the first time, at a STAT event Tuesday, to allegations in a new book about why he was forced to resign.
    STAT · 2mo ago↗ source
  • Trump’s cuts to foreign aid are undermining the Ebola response, insiders say
    President Trump's cuts to foreign aid probably hampered the detection of the Ebola outbreak and the response to it.
    STAT · 2mo ago↗ source
  • STAT+: Virginia governor vetoes legislation to create an advisory panel to lower the cost of prescription drugs
    Virginia's governor vetoed a closely watched effort to create an advisory panel to lower prescription drug costs.
    STAT · 2mo ago↗ source
  • STAT+: This spine surgery usually costs $1,400. Under No Surprises Act arbitration? $34,000
    A new analysis shows how some clinicians are cashing in on a new process designed to protect patients from surprise bills.
    STAT · 2mo ago↗ source
  • How AI helped treat a newborn’s ultra rare disease. ‘It was almost like a light switch.’
    The parents of Jorie Kraus told the audience at STAT's Breakthrough Summit West about how AI helped their daughter who was born with a rare disease.
    STAT · 2mo ago↗ source
  • TrumpRx adds hundreds of generic medicines to site
    The Trump administration is significantly building the portfolio of drugs available through its direct-to-consumer platform TrumpRx, adding more than 600 generic medicines. President Donald Trump o…
    Endpoints · 2mo ago↗ source
  • Another Paragon offshoot chooses reverse merger, this time for migraine drugs
    They say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers. The hub-and-spoke biologics company is moving its migraine drug offshoot, Mentari Therapeutics, onto the p…
    Endpoints · 2mo ago↗ source
  • Acceleron leaders and Westlake jumpstart new IPF biotech
    After success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million Series A round,…
    Endpoints · 2mo ago↗ source
  • STAT+: Canadian medical societies lack sufficient conflict-of-interest policies, study finds
    Most Canadian medical societies lack comprehensive policies governing conflicts of interest, and many policies are generally fragmented and narrow in scope, according to a new analysis.
    STAT · 2mo ago↗ source
  • STAT+: At a time of tumult at FDA, a former commissioner is hopeful it’s on a better path
    With the FDA facing upheaval and personnel exits, former commissioner David Kessler sees an opportunity whereby the agency can make a turn for the better.
    STAT · 2mo ago↗ source
  • STAT+: TrumpRx adds generic drugs
    A deal with Mark Cuban, Amazon Pharmacy, and GoodRx is boosting TrumpRx's offerings.
    STAT · 2mo ago↗ source
  • The state of consumer health
    On Thursday, the Health Tech team led a series of conversations at the Financial Times’ US Pharma and Biotech Summit, held in collaboration with Endpoints News. The sessions focused on ...
    Endpoints · 2mo ago↗ source
  • Q&A: Novo research chief Petersen says streamlined R&D speeds discovery
    Just as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganize its R&D activities, merging the teams that focused on early ...
    Endpoints · 2mo ago↗ source
  • Wave aims for monthly dosing with RNA editing treatment for AATD
    Wave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting it can dose its genetic therapy monthly. Peo…
    Endpoints · 2mo ago↗ source
  • Full-Life Technologies raises $150M; Quince's reboot with pulmonary drug
    Plus, news about Accro Bioscience, Hansa Biopharma, Shanghai Best-Link Bioscience and UCB. Full-Life Technologies gets $150M: The radiotherapy company has raised $110 million in a Series D round an…
    Endpoints · 2mo ago↗ source
  • STAT+: Dexcom CEO hints at future uses for CGM
    In this edition of STAT Health Tech: Takeaways from a conversation with Dexcom CEO, and updates on WiSeR, and Epic's market share.
    STAT · 2mo ago↗ source